Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isconova and Genocea Biosciences have widened their existing agreement, under which Isconova has given license for using its Matrix M to Genocea Biosciences in vaccines targeting two additional diseases.
Subscribe to our email newsletter
Currently, Genocea has the right to use Matrix M in vaccines targeting six infectious diseases including programs in its pipeline for herpes simplex virus type-2, Chlamydia trachomatis, and Streptococcus pneumoniae.
With this expansion, Genocea has got license to use Matrix M in vaccines for malaria and gonorrhoea.
Genocea CEO Chip Clark said a safe and effective adjuvant that elicits strong B and T cell immune response is essential to their aim to prevent or treat infectious diseases.
Isconova CEO Lena Soderstrom said they are pleased that a vaccine discovery and development company Genocea has selected Isconova’s Matrix M for use in two additional diseases, thus confirming the strengths of their products.